Acurx Pharmaceuticals (ACXP) AGM 2026 summary

Opening remarks and agenda

• Virtual meeting called to order at 10:00 A.M. Eastern Time; formal business and votes preceded general questions.

• Agenda: elect two Class II directors for three-year terms ending in 2029 and ratify CohnReznick LLP as independent auditor for FY ending Dec. 31, 2026.

• Quorum confirmed with 2,890,899 shares present in person or by proxy, representing ~52.8% of outstanding common stock.

Board and executive committee updates

• Dave Luci and Dr. Jack Dean were elected as Class II directors to serve through the 2029 AGM and until successors are elected and qualified.

• Board members present included Dr. Jack Dean, Tom Harrison, Carl Sailer, Bob DeLuccia and Dave Luci; management attendees included CFO Rob Shawah and Controller Sue Yee.

Corporate governance

• Bylaws require advance written notice for stockholder business; no such notice was received, limiting voting to the two proxy-statement proposals.

• Stockholders could vote or change votes through the meeting portal until polls closed; Broadridge Financial Solutions tabulated votes and served as Inspector of Elections.

• Meeting was not a public forum under SEC Regulation FD; material non-public information would not be provided.